Find upcoming conference

Meetings and conferences calendar

Below is a calendar of upcoming meetings and conferences that you may be interested in attending. Because dates and locations are subject to change, it is recommended that you confirm this information before making travel plans.

2008-2009 CALENDAR OF EVENTS

Addiction Psychiatrists and Specialists
Meeting	2008 Date and Location	2009 Date and Location
APA American Psychological Association 117th Annual Convention		August 6–9, 2009 Toronto, Canada
APA American Psychiatric Association 162nd Annual Meeting		May 16–21, 2009 San Francisco,CA
RSA Research Society on Alcoholism 32nd Annual Scientific Meeting		June 20–25, 2009 San Diego, CA
AAAP American Academy of Addiction Psychiatry 19th and 20th Annual Meeting	December 4–7, 2008 Boca Raton, FL	December 3–6, 2009 Los Angeles, CA
USPsych U.S. Psychiatric & Mental Health Congress Annual Meeting	October 30–November 2, 2008 San Diego, CA	TBD
ACNP American College of Neuropsychopharmacology 47th and 48th Annual Meeting	December 7–11, 2008 Scottsdale, AZ	December 6–10, 2009 Hollywood, FL
ASAM American Society of Addiction Medicine 40th Annual Medical Scientific Conference		April 30–May 3, 2009 New Orleans, LA

Counselors and Social Workers
Meeting	2008 Date and Location	2009 Date and Location
AAMFT American Association for Marriage and Family Therapy Annual Conference	October 30–November 2, 2008 Memphis, TN	October 1–4, 2009 Sacramento, CA
CPDD College on Problems of Drug Dependence 71st Annual Meeting		June 20–25, 2009 Reno/Sparks, NV
ASAP Alcoholism and Substance Abuse Providers (of NY State) Annual Conference		January 25–28, 2009 New York, NY
AATOD National Conference of the American Association for the Treatment of Opioid Dependence		April 25–29, 2009 New York, NY
SSWR Society for Social Work and Research 13th Annual Conference		January 16–18, 2009 New Orleans, LA
NAADAC, KAAP, and NALGAP National Association of Alcoholism and Drug Abuse Counselors, Kansas Association of Addiction Professionals, and the National Association of Lesbian and Gay Addiction Professionals, Joint Annual Conference	August 28–31, 2008 Overland Park, KS	August 19–22, 2009 Salt Lake City, UT
AMERSA Association for Medical Education and Research in Substance Abuse Annual Conference	November 6–8, 2008 Washington, DC	TBD
ACA American Counseling Association Annual Conference		March 19–23, 2009 Charlotte, NC
Primary Care Physicians and Nurse Practitioners
AAPA American Academy of Physician Assistants Annual Conference		May 23–28, 2009 San Diego, CA
ACNP American College of Nurse Practitioners National Clinical Conference	October 29–November 2, 2008 Nashville, TN	October 7–11, 2009 Albuquerque, NM
AANP American Academy of Nurse Practitioners 24th National Annual Conference		June 17–21, 2009 Nashville, TN
AAFP American Academy of Family Physicians Scientific Assembly		October 14–18, 2009 Boston, MA
CSAM California Society of Addiction Medicine, Addiction Medicine Review Course	October 22–25, 2008 Newport Beach, CA	TBD
NAATP National Association of Addiction Treatment Providers, Addiction Treatment Leadership Conference		May 17–20, 2009 West Palm Beach, FL
FSPHP Federation of State Physician Health Programs Annual Meeting and Conference		April 27–30, 2009 New Orleans, LA
NADCP National Association of Drug Court Professionals 15th Annual Training Conference		June 10–13, 2009 Anaheim, CA
SAAS/NIATx State Association of Addiction Services and the Network for the Improvement of Addiction Treatment		TBD
NASADAD, NPN, and NTN National Association of State Alcohol/Drug Abuse Directors, National Prevention Network, and National Treatment Network		June 4–7, 2009 Syracuse, NY
ACMHA American College of Mental Health Administration Annual Summit		March 12–19, 2009 Santa Fe, NM

INDICATION1

VIVITROL® is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

Patients should not be actively drinking at the time of initial VIVITROL administration.

Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.

IMPORTANT SAFETY INFORMATION FOR VIVITROL1

VIVITROL is contraindicated in patients receiving opioid analgesics or with current physiologic opioid dependence, patients in acute opiate withdrawal, any individual who has failed the naloxone challenge test or has a positive urine screen for opioids, or in patients who have previously exhibited hypersensitivity to naltrexone PLG, carboxymethylcellulose or any other components of the diluent.

VIVITROL patients must be opioid free for a minimum of 7-10 days before treatment. Attempts to overcome opioid blockade due to VIVITROL may result in a fatal overdose. In prior opioid users, use of opioids after discontinuing VIVITROL may result in a fatal overdose because patients may be more sensitive to lower doses of opioids. Patients requiring reversal of the VIVITROL blockade for pain management should be monitored by appropriately trained personnel in a setting equipped for cardiopulmonary resuscitation.

Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses

Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects.

The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses.

Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.

VIVITROL is administered as a gluteal intramuscular injection. Inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions. VIVITROL must be injected using the customized needle provided in the carton. Because needle length may not be adequate due to body habitus, each patient should be assessed prior to each injection to assure that needle length is adequate for intramuscular administration. VIVITROL injection site reactions may be followed by pain, tenderness, induration, swelling, erythema, bruising or pruritus; however, in some cases injection site reactions may be very severe. Injection site reactions not improving may require prompt medical attention, including in some cases surgical intervention.

Consider the diagnosis of eosinophilic pneumonia if patients develop progressive dyspnea and hypoxemia. In an emergency situation in patients receiving VIVITROL, suggestions for pain management include regional analgesia or use of non-opioid analgesics. Alcohol dependent patients, including those taking VIVITROL, should be monitored for the development of depression or suicidal thoughts. Caution is recommended in administering VIVITROL to patients with moderate to severe renal impairment.

The most common adverse events associated with VIVITROL in clinical trials were nausea, vomiting, headache, dizziness, asthenic conditions and injection site reactions.

Please see VIVITROL Full Prescribing Information, including box warning by clicking on the link at the bottom of this page.